Introduction {#S1}
============

Adeno-associated virus 2 (AAV2), a non-pathogenic human parvovirus, contains a single-stranded DNA genome, and possesses a wide tissue-tropism that transcends the species barrier^[@R1]^. Recombinant AAV2 vectors have gained attention as a promising vector system for the potential gene therapy of a variety of human diseases, and are currently in use in a number of gene therapy clinical trials^[@R2]^. More recently, several additional AAV serotypes have been isolated, and have been shown to transduce specific cell types efficiently^[@R3]-[@R8]^. Whereas various steps in the life cycle of AAV2 are reasonably well understood^[@R9]-[@R26]^, less is known about the other serotypes.

Of the 10 commonly used AAV serotypes, AAV3 has been reported to transduce cells and tissues poorly^[@R27],[@R28]^. However, recent studies from our laboratory revealed that AAV3 vectors transduce established human hepatoblastoma (HB) and human hepatocellular carcinoma (HCC) cell lines as well as primary human hepatocytes extremely efficiently^[@R29]^. Subsequently, we documented that AAV3 infection was strongly inhibited by hepatocyte growth factor (HGF), HGF receptor (HGFR) specific siRNA, and anti-HGFR antibody, which suggested that AAV3 utilizes HGFR as a cellular receptor/co-receptor for viral entry^[@R30]^. The precise underlying molecular mechanisms of HGFR-mediated viral entry as well as additional steps in the life cycle of AAV3 remain unexplored.

Others and we have previously reported that the ubiquitin-proteasome pathway plays a crucial role in intracellular trafficking of AAV vectors^[@R15],[@R31],[@R32]^. We have also reported that intact AAV2 capsids can be phosphorylated at tyrosine residues by epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK), and that tyrosine-phosphorylation of AAV capsids negatively affects viral intracellular trafficking and transgene expression. These observations led to the suggestion that tyrosine-phosphorylation is a signal for ubiquitination of AAV capsids followed by proteasome-mediated degradation^[@R32],[@R33]^. This led to the hypothesis that mutations of the surface-exposed tyrosine residues (Y) to phenylalanine (F) might allow the vectors to evade phosphorylation, ubiquitination and proteasome-mediated degradation. Indeed, mutations of the surface-exposed tyrosine residues in AAV2 vectors led to high-efficiency transduction at lower doses both in HeLa cells *in vitro* and murine hepatocytes *in vivo*^[@R34]^. Therapeutic levels of expression of human factor IX have been obtained in several different strains of mice using the single and multiple tyrosine-mutant AAV2 vectors^[@R34],[@R35]^. Additional studies have corroborated that similar Y-F mutations in AAV serotypes 6, 8 and 9 also lead to augmented transgene expression^[@R36]-[@R38]^. Six of 7 surface-exposed tyrosine residues in AAV2 are also conserved in AAV3, but their involvement in AAV3-mediated transduction has not been evaluated.

In this study, we report that: (i) AAV3 vector-mediated transduction is dramatically increased in T47D cells, a human breast cancer cell line that expresses undetectable levels of the endogenous hHGFR^[@R39]^, following stable transfection and over-expression of hHGFR; (ii) the tyrosine kinase activity associated with hHGFR negatively affects the transduction efficiency of AAV3 vectors; (iii) the use of proteasome inhibitors significantly improves AAV3 vector-mediated transduction; (iv) site-directed mutagenesis of three surface-exposed tyrosine residues on the AAV3 capsid leads to improved transduction efficiency; (v) a specific combination of two tyrosine-mutations further improves the extent of transgene expression; and (vi) AAV3 vectors efficiently transduce human HB and HCC tumors in a murine xenograft model *in vivo*, following both intratumoral or systemic administration. These optimized AAV3 vectors may be useful for the potential gene therapy of liver cancer in humans.

Results {#S2}
=======

Human HGFR is required for AAV3 infectivity {#S3}
-------------------------------------------

We recently provided preliminary evidence that AAV3 utilizes human hepatocyte growth factor receptor (HGFR) as a cellular co-receptor^[@R30]^. To unequivocally corroborate this contention, we used a human breast cancer cell line, T47D, which expresses undetectable levels of hHGFR^[@R39]^, as well as T47D cells stably transfected with a hHGFR expression plasmids (T47D+hHGFR)^[@R39]^. The expression of hHGFR protein in the established cell line, T47D+hHGFR, was confirmed by Western blot analysis (data shown below in [Fig 2C](#F2){ref-type="fig"}). Equivalent numbers of T47D and T47D+hHGFR cells were transduced with various multiplicities-of-infection (MOI) of self-complementary (sc) AAV3-CBAp-EGFP vectors under identical conditions and transgene expression was determined 72 hrs post-transduction. These results, shown in [Fig. 1A](#F1){ref-type="fig"}, document that the transduction efficiency of AAV3 vectors is \~8-13-fold higher in cells that express hHGFR than those that do not. AAV3 vector-mediated transduction of T47D+hHGFR cells could be completely blocked in the presence of 5 μg/ml of hHGF ([Fig. 1B](#F1){ref-type="fig"}). Taken together, these data provide conclusive evidence that cell surface expression of hHGFR is required for successful transduction by AAV3 vectors.

Inhibition of HGFR protein tyrosine kinase activity enhances the transduction efficiency of AAV3 vectors {#S4}
--------------------------------------------------------------------------------------------------------

We next wished to examine whether in addition to the extracellular domain, the intracellular domain of HGFR, which contains protein tyrosine kinase activity, is also involved in AAV3 infection. Binding of its ligand, HGF, results in dimerization of the receptor and intermolecular trans-phosphorylation of multiple tyrosine residues in the intracellular domain^[@R40]^. T47D+hHGFR cells were treated for 2 hrs with increasing concentrations of a specific HGFR kinase inhibitor, BMS-77760707 (BMS)^[@R41],[@R42]^. Cells were subsequently infected with scAAV3 vectors at 2,000 vgs/cell. These results are shown in [Fig. 2A](#F2){ref-type="fig"}. It is evident that BMS-777607-treatment led to \~2-fold increase in AAV3 transduction efficiency. Although the p-value is higher when BMS-777607 was used at the highest concentration of 10 μM, compared with the lower concentration of 1 μM, this change is most likely due to drug toxicity. In previous studies, it has been reported that BMS-777607 treatment had no significant effect on cell growth at doses ≤1 μM. However, doses of 10 μM did result in significant reduction in cell proliferation, which suggests that this concentration is toxic to cells^[@R43]^. In the next experiment, to rule out any possible non-specific nature of this drug, the parental T47D cells were included as a control. Both cell types were treated with 1 μM BMS-777607 for 2 hrs and then infected with scAAV3 vectors at 10,000 vg/cell. The results, shown in [Fig. 2B](#F2){ref-type="fig"}, indicated that whereas BMS-777607-treatment significantly enhances AAV3 infectivity in T47D+hHGFR cells, it has no effect in T47D cells that lack expression of hHGFR.

We also wished to examine whether inhibition of the HGFR kinase led to alterations in the phosphorylation status of specific cellular proteins involved in the downstream signaling pathway. Total and phosphorylation levels of the HGFR protein in both T47D and T47D+hHGFR lysates were determined following a 2-hr drug-incubation period. Activation of signaling pathways downstream from HGFR kinase, ERK1/2 and Akt, were analyzed using phosphorylation-specific antibodies. These results, shown in [Fig. 2C](#F2){ref-type="fig"}, confirmed that whereas little expression of hHGFR occurs in T47D cells, the level of expression is significantly higher in T47D+hHGFR cells for both total HGFR and phosphorylated HGFR, which is consistent with previously published reports^[@R39]^. Treatment of T47D+hHGFR cells with BMS-777607 completely blocked the phosphorylation of HGFR but not total HGFR. In addition, BMS-777607-treatment had no effect on the expression of phosphorylated AKT and ERK1/2. These results suggest that the enhancement of AAV3 vector infectivity by the BMS-777607-treatment is due to inhibition of HGFR kinase.

To date, only AAV2 has been reported to use hHGFR as a co-receptor^[@R44]^. The roles of hHGFR and hHGFR kinase inhibitor on other AAV serotypes are not known. To rule out any non-specific enhancement of transduction by BMS-777607, other serotypes of AAV, which are not dependent on HGFR, as well as AAV2 vectors were compared for transduction efficiency following treatment of cells with BMS-777607. These results, shown in [Fig. 3](#F3){ref-type="fig"}, indicate that whereas AAV2 and AAV3 vectors can efficiently transduce T47D+hHGFR cells, other serotypes (AAV4-AAV9) can only transduce these cells at a very low efficiency. This result suggests that hHGFR is not involved in the life cycle of these AAV serotypes. Treatment of cells with BMS-777607 significantly increased the transduction efficiency of both AAV2 and AAV3 vectors, but not the other AAV serotypes, which suggests that the effect of the BMS-777607-treatment is AAV serotype-specific.

Proteasome inhibitors increase the transduction efficiency of AAV3 vectors {#S5}
--------------------------------------------------------------------------

Previous studies by others and us have shown that proteasome inhibitors, such as MG132, can significantly enhance the transduction efficiency of AAV2 vectors by facilitating intracellular trafficking^[@R31],[@R45]^. To evaluate whether MG132 can also improve AAV3 trafficking in target cells, Huh7, a well-established human hepatocellular carcinoma cell line^[@R46]^, and Hep293TT, a recently established human hepatoblastoma cell line^[@R47]^, were either mock-treated or treated with increasing concentrations of MG132. Following a two-hour treatment, cells were infected with scAAV3-EGFP vectors. HeLa cells, treated with 5 μM MG132 and transduced with scAAV2 vectors, were included as a positive control. Transgene expression was determined by fluorescence microscopy 72 hrs post-transduction. These data are shown in [Fig. 4A and 4B](#F4){ref-type="fig"}. As can be seen, pretreatment with MG132 significantly increased the transduction efficiency of scAAV2 vectors in HeLa cells, which is consistent with our previously published studies^[@R31]^. Interestingly, a dose-dependent increase in the transduction efficiency of scAAV3 vectors in both Huh7 and Hep293TT cells occurred following MG132-treatment, suggesting that AAV3 vectors also undergo ubiquitination followed by proteasome-mediated degradation.

Previous studies from our laboratory have also shown that inhibition of EGFR-PTK signaling by Tyrphostin 23 (Tyr23), a specific inhibitor of EGFR-PTK^[@R48]^, modulates the Ub/proteasome pathway, which in turn, facilitates intracellular trafficking and transgene expression mediated by AAV2 vectors^[@R31]^. Hep293TT cells were mock-treated or treated with Tyr23 for 2 hrs and transduced with scAAV3 vectors. HeLa cells, pretreated with Tyr23 and transduced with scAAV2 vectors, were included as appropriate controls. Transgene expression was determined 72 hrs post-transduction. These results, shown in [Fig. 4C and 4D](#F4){ref-type="fig"}, indicate that Tyr23-treatment led to a significant increase in the transduction efficiency of both scAAV2 and scAAV3 vectors. The increased transgene expression was independent of vector entry, since there was no significant difference in the amounts of internalized viral DNA in the presence or absence of either MG132 or Tyr23 (data not shown). These results further corroborate the involvement of the host cell Ub/proteasome machinery in the life cycle of AAV3 vectors as well.

Site-directed mutagenesis of surface-exposed tyrosine residues significantly improves the transduction efficiency of scAAV3 vectors {#S6}
-----------------------------------------------------------------------------------------------------------------------------------

Recent studies from our laboratory have shown that there are 7 surface-exposed tyrosine residues (Y252, Y272, Y444, Y500, Y700, Y704 and Y730) on AAV2 capsids that are phosphorylated by EGFR-PTK and negatively affect the transduction efficiency of AAV2 vectors^[@R34]^. Alignment of amino acid sequences from AAV2 and AAV3 capsids indicated that six of seven tyrosine residues (Y252, Y272, Y444, Y701, Y705 and Y731) are conserved in AAV3 capsid ([Table 1](#T1){ref-type="table"}). One tyrosine residue, Y500 in AAV2, is present as F501 in AAV3. Since we and others have shown that Y-F mutations in several AAV serotypes enhance transgene expression by circumventing ubiquitination and proteasome-mediated degradation^[@R34],[@R36]-[@R38]^, we reasoned that mutation of F501 back to a tyrosine residue would reduce the transduction efficiency of AAV3 vectors. This hypothesis was tested by generating a mutant AAV3 vector in which the phenylalanine residue was substituted with a tyrosine residue (F501Y). The transduction efficiency of the mutant vector was compared with its wild-type (WT) AAV3 counterpart using Huh7 cells under identical conditions. As can be seen in [Fig. 5A](#F5){ref-type="fig"}, the extent of the transgene expression mediated by the F501Y mutant vector was reduced by \~50% compared with the WT AAV3 vector.

To further test our hypothesis that tyrosine-mutations on AAV3 capsids would lead to decreased EGFR-PTK-mediated phosphorylation followed by reduced ubiquitination and impaired proteasome-mediated degradation resulting in increased transgene expression, we modified all six surface-exposed tyrosine residues on AAV3 capsids and substituted with phenylalanine residues (tyrosine-phenylalanine, Y-F). Each of the single tyrosine-mutant vectors encapsidating scAAV2-CBAp-EGFP genomes could be successfully packaged. Vector titers for each of the mutants were determined by both quantitative DNA slot blots and qPCR, and no significant differences in the packaging efficiency were observed (data not shown). The transduction efficiency of each of the tyrosine-mutant vectors was analyzed and compared with the WT scAAV3-CBAp-EGFP vector in both Huh7 ([Fig. 5B](#F5){ref-type="fig"}) and Hep293TT ([Fig. 5C](#F5){ref-type="fig"}) cells under identical conditions. From these results, it is evident that, the transduction efficiency of three of the tyrosine-mutant vectors (Y701F, Y705F and Y731F) is significantly higher compared with the WT scAAV3 vector. Specifically, the transduction efficiency of Y731F vector was \~8-fold higher than the WT vector, followed by Y705F (\~3-fold) and Y701F (\~2-fold) vectors.

Multiple-mutations in surface-exposed tyrosine residues further improve the transduction efficiency of AAV3 vectors {#S7}
-------------------------------------------------------------------------------------------------------------------

In our recently published studies with Y-F mutant AAV2 vectors, we observed that specific combinations of the most efficient single-mutations of surface-exposed tyrosine residues further augmented the transduction efficiency of AAV2 vectors^[@R35]^. To examine whether a similar enhancement could be achieved with AAV3 vectors, we generated the following double- and triple-mutant AAV3 vectors: Y701+731F, Y705+731F, and Y701+705+731F. Each of these mutant vectors was packaged to similar titers, as determined by both quantitative DNA slot blots and qPCR (data not shown). The transduction efficiency of these multiple-mutants was compared with the WT and the Y731F single-mutant AAV3 vectors in Huh7 cells under identical conditions. These results are shown in [Fig. 6A](#F6){ref-type="fig"}. As can be seen, whereas the Y731F mutation significantly increased the transduction efficiency of AAV3 vectors, as observed before, only one of the double-mutations (Y705+731F) led to an additional significant increase in transgene expression. Interestingly, the transduction efficiency of both the double-mutant (Y701+731F) and the triple-mutant (Y701+705+731F) vectors was reduced to levels similar to the WT AAV3 vector. The best performing single and multiple tyrosine-mutants on human liver cancer cells were then evaluated for transduction of T47D and T74D+hHGFR cells ([Fig. 6B](#F6){ref-type="fig"}). Similar to human liver cancer cells, the tyrosine-mutant rAAV3 vectors led to high-efficiency transduction of both cell types, with or without hHGFR expression.

To examine the possibility whether the observed enhanced transduction efficiency of the Y-F mutant vectors was due to the involvement of one or more additional putative cellular receptor/co-receptor functions, the WT, Y731F, and Y705+731F mutant scAAV3-CBAp-EGFP vectors were used to transduce Huh7 cells in the absence or the presence of 5 μg/ml hHGF under identical conditions. These results are shown in [Fig. 6C](#F6){ref-type="fig"}. As is evident, the presence of hHGF dramatically inhibited the transduction efficiency and transgene expression of all three AAV3 vectors, which is consistent with the interpretation that the tyrosine-mutant vectors also utilize hHGFR as a cellular receptor/co-receptor for viral entry.

AAV3 vectors transduce human liver tumors in murine xenograft models *in vivo* {#S8}
------------------------------------------------------------------------------

It was important to obtain proof-of-principle whether AAV3 vectors could also transduce human HB and HCC tumors in a xenograft mouse model *in vivo*. To this end, \~5×10^[@R6]^ HCC (Huh7) or HB (Hep293TT) cells were injected sub-cutaneously in NOD/Scid gamma (NSG) mice. Four-weeks later, when tumors were clearly visible and palpable in both groups of animals, \~2×10^10^ vgs of scAAV3-CBAp-EGFP vectors were injected directly into tumors. Four-days post-vector injections, tumors were excised, and thin sections were examined under a fluorescence microscope. These results, shown in [Fig. 7](#F7){ref-type="fig"}, indicate that AAV3 provides an effective means to transduce both human HCC ([Fig. 7A](#F7){ref-type="fig"}) and HB ([Fig. 7B](#F7){ref-type="fig"}) tumors *in vivo*. Consistent with the i*n vitro* data, the transduction efficiency of AAV3 vectors was higher in Hep293TT cell-derived tumors than that in Huh7 cell-derived tumors.

Optimized tyrosine-mutant AAV3 vectors are highly efficient in transducing human liver tumors in a murine xenograft model *in vivo* {#S9}
-----------------------------------------------------------------------------------------------------------------------------------

Next, the best performing double tyrosine-mutant AAV3 vectors were further evaluated *in vivo* for xenograft human liver tumors gene transfer. In the first set of experiments, \~5×10^10^ vgs of either the wild-type (WT) scAAV3- or Y705+731F-AAV3-CBAp-EGFP vectors were intratumorally injected in NSG mice bearing human HB (Hep293TT) tumors. Four-days post-vector injections, tumors were excised, and thin sections were examined under a fluorescence microscope ([Fig. 7C](#F7){ref-type="fig"}). As can be seen, tumors injected with the WT-AAV3 vectors exhibited detectable levels expression of EGFP. The transduction efficiency of the double tyrosine-mutant AAV3 vectors was significantly higher compared with the WT AAV3 vectors, which is consistent with our *in vitro* data.

In the second set of experiments, \~5×10^11^ vgs of either the WT-scAAV3- or the Y705+731F-scAAV3-CBAp-EGFP vectors were injected via the tail-vein in NSG mice bearing human HB (Hep293TT) tumors. Phosphate-buffered saline (PBS) injections were used as an appropriate control. As can be seen in [Fig. 8](#F8){ref-type="fig"}, whereas little trangene expression occurred in tumors from mice injected with pBS ([Fig. 8A](#F8){ref-type="fig"}), direct tumor-targeting could be achieved following systemic administration of AAV3 vectors. The transduction efficiency of the optimized tyrosine-mutant AAV3 vectors ([Fig. 8C](#F8){ref-type="fig"}), once again, was significantly higher than that of the WT AAV3 vectors ([Fig. 8B](#F8){ref-type="fig"}). These data suggest that the observed increased transduction efficiency of tyrosine-mutant AAV3 vectors is independent of viral administration route. Additional studies are warranted with the Y705+731F mutant scAAV3 vectors containing a therapeutic gene to further evaluate their safety and efficacy these vectors for the potential gene therapy of HB and HCC.

Discussion {#S10}
==========

Recombinant vectors based on AAV serotype 2 are currently in use in a number of gene therapy clinical trials^[@R2]^, and have recently shown remarkable efficacy in the treatment of Leber's congenital amaurosis^[@R26],[@R49],[@R50]^. However, concerns have been raised with reference to the humoral response to AAV2 vectors based on the high prevalence of sero-positivity in the general population (\~80 to 90%)^[@R51]-[@R53]^. The discovery of many novel AAV serotypes has prompted the development of AAV vectors to circumvent this potential problem^[@R3]-[@R8]^. For example, recombinant AAV8 vectors were recently reported to be therapeutic in a mouse model of liver cancer^[@R54]^. However, several groups have described various strategies to target human liver cancer cells in murine models using AAV2 vectors^[@R55]-[@R63]^. In our pursuit to identify the most efficient AAV serotype to target human liver cancer cells, we observed that three different human liver cancer cell lines could be transduced extremely efficiently by AAV3 vectors^[@R29]^. We subsequently identified human hepatocyte growth factor receptor (hHGFR) as a cellular co-receptor for AAV3 infection^[@R30]^. However, the precise role of hHGFR, especially the role of tyrosine kinase activity associated with the intracellular domain of hHGFR, in AAV3-mediated transduction remained unclear. Here, we present a more detailed account of the AAV3-hHGFR interactions, and describe the development of an optimal AAV3 vector for its potential use in targeting human liver cancer cells.

HGFR is a trans-membrane receptor tyrosine kinase, and binding of its ligand, HGF, results in dimerization of the receptor and intermolecular trans-phosphorylation of multiple tyrosine residues in the intracellular domain^[@R64]^. Whereas it is clear that AAV3 capsid interacts with the extracellular domain of hHGFR, it is less clear whether AAV3-binding to hHGFR also triggers its activation and phosphorylation of the downstream target proteins. Our data do indeed demonstrate that suppression of the hHGFR-PTK activity leads to a modest increase in AAV3 vector-mediated transgene expression. In this context, it is of interest to note that the transduction efficiency of AAV3 vectors is significantly higher in a more recently established human hepatoblastoma (HB) cell line, Hep293TT, compared with that in a HB cell line, Huh6, which was established nearly three decades ago. Although subtle differences might exist between the two cell lines, we have identified specific mutations in the tyrosine kinase domain of hHGFR in Hep293TT cells, which render it inactive, and that the hHGFR-specific kinase inhibitor, BMS-777607, which augments the transduction efficiency in Huh6 cells, has little effect on AAV3 transduction efficiency in Hep293TT cells (data not shown).

Despite the utilization of two distinct cellular growth factor receptors as co-receptors by AAV2 (hFGFR1) and AAV3 (hHGFR), the two serotypes appear to share certain post-receptor entry and intracellular trafficking pathways. For example, both capsids become phosphorylated at tyrosine residues by EGFR-PTK, presumably in the late endosomes, followed by ubiquitination, which leads to proteasome-mediated degradation^[@R33]^. However, although 6 of 7 surface-exposed tyrosines in AAV2 are conserved in AAV3, the patterns of behavior of the corresponding Y-F mutants are somewhat divergent. For example, Y730F (for AAV2) and Y731F (for AAV3) are the most efficient single-mutants, followed by Y444F (for AAV2), and Y705F (for AAV3), the transduction efficiency of Y444F (for AAV3) remains unaltered. Similarly, whereas the transduction efficiency of the Y730+444F double-mutant (for AAV2) is not significantly different from that of Y730F, the transduction efficiency of the Y705+731F double-mutant (for AAV3) is significantly higher than Y731F. Furthermore, the Y730+500+444F triple-mutant (for AAV2) is the most efficient, the Y731+501+705F triple-mutant (for AAV3) is the most efficient, the Y501 residue having already been mutated in the WT AAV3 capsid. The molecular basis for these observed differences are not readily apparent, and further studies are warranted to gain a better understanding of the underlying molecular mechanisms. Interestingly, even the WT AAV3 vectors were able to transduce human liver tumors reasonably well in a mouse xenograft model *in vivo* following intratumor injection. However, we showed evidence that the tyrosine-mutant vector resulted in higher gene transfer efficiency *in vivo*. It is tempting to speculate that the use of the optimized tyrosine-mutant AAV3 vectors containing a pro-apoptotic gene would lead to a therapeutic effect in human liver tumors *in vivo*.

Human liver cancer, especially hepatocellular carcinoma (HCC), is one of the most aggressive malignant tumors. The major obstacle to survival with HCC is recurrence after HCC resection^[@R65]^. Thus, transduction of 100% of target cells is desirable in order to totally eliminate the tumor. In our previous studies, we have observed that melittin, a toxic peptide derived from bee venom, inhibits the viability and motility of HCC cells both *in vitro* and *in vivo* via the suppression of Rac1-dependent pathway^[@R66]^ and up-regulation of mitochondria membrane protein 7A6^[@R67]^. We have also demonstrated that melittin can induce apoptosis of HCC cells potentially by activating CaMKII/TAK1/JNK/p38 signaling pathway^[@R68]^. Based on our previous studies with recombinant adenovirus vectors containing the melittin gene driven by a liver cancer cell-specific promoter to achieve specific killing of liver cancer cells both *in vitro* and *in vivo*^[@R69]^, we now wish to develop optimized tyrosine-mutant AAV3-melittin vectors under the control of a liver cancer cell-specific promoter to selectively target both primary and metastatic liver cancer.

Material and Methods {#S11}
====================

Cell lines and cultures {#S12}
-----------------------

Human cervical cancer (HeLa) and hepatocellular carcinoma (Huh7) cell lines were purchased from American Type Culture Collection (Manassas, VA, USA), and maintained in complete DMEM medium (Mediatech Inc., Manassas, VA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO, USA), 1% penicillin and streptomycin (P/S, Lonza, Walkersville, MD). A newly established human hepatoblastoma (Hep293TT) cell line^[@R47]^ was generously provided by Dr. Gail E. Tomlinson, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA), and was maintained in complete RPMI medium 1640 (Invitrogen, Camarillo, CA) supplemented with 15% heat-inactivated FBS (Sigma-Aldrich, St. Louis, MO, USA), 1% penicillin and streptomycin (P/S, Lonza, Walkersville, MD). Cells were grown as adherent cultures in a humidified atmosphere at 37°C in 5% CO~2~ and were sub-cultured after treatment with trypsin-versene mixture (Lonza, Walkersville, MD) for 2-5 min at room temperature, washed and re-suspended in complete medium. A human breast cancer cell line, T47D, and T47D cells stably transfected with a hHGFR expression plasmid (T47D+hHGFR), were maintained in complete DMEM medium (Mediatech Inc., Manassas, VA, USA) with or without 600 μg/ml of G418, supplemented with 10% heat-inactivated fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO, USA), 1% penicillin and streptomycin (P/S, Lonza, Walkersville, MD).

Recombinant AAV plasmids and vectors {#S13}
------------------------------------

Recombinant AAV3 packaging plasmid and recombinant AAV2-CBAp-EGFP vector plasmid were generously provided respectively by Drs. R. Jude Samulski and Xiao Xiao, University of North Carolina at Chapel Hill, Chapel Hill, NC. Highly purified stocks of scAAV2 and scAAV3 vectors containing the enhanced green fluorescence protein (EGFP) gene driven by the chicken β-actin promoter (CBAp) were packaged by the calcium phosphate triple-plasmid transfection protocol described previously^[@R70],[@R71]^. The physical particle titers of recombinant vector stocks were determined by quantitative DNA slot-blot analyses^[@R71]^.

Construction of surface-exposed tyrosine residue mutant AAV3 capsid plasmids {#S14}
----------------------------------------------------------------------------

A two-stage procedure, based on QuikChange II site-directed mutagenesis (Stratagene) was performed by using plasmid pAAV3 as described previously^[@R29],[@R30]^. Briefly, in stage one, two PCR extension reactions were performed in separate tubes for each mutant. One tube contained the forward PCR primer and the other contained the reverse primer ([Table 2](#T2){ref-type="table"}). In stage two, the two reactions were mixed and a standard PCR mutagenesis assay was carried out as the manufacturer's instructions. PCR primers were designed to introduce changes from tyrosine to phenylalanine residues and a silent change to create a new restriction endonuclease site for screening purposes ([Table 2](#T2){ref-type="table"}). All mutants were screened with the appropriate restriction enzyme and were sequenced before use.

AAV vector transduction assays {#S15}
------------------------------

Huh7 or HeLa cells were seeded in 96-well plates at a concentration of 5,000 cells per well in complete DMEM medium. AAV infections were performed in serum- and antibiotic-free DMEM medium. Hep293TT cells were seeded in 96-well plates at a concentration of 10,000 cells per well in complete RPMI medium. The infections were performed in serum- and antibiotic-free RPMI medium. The expression of EGFP was analyzed by direct fluorescence imaging 72 hrs post-transduction.

Western blot analyses {#S16}
---------------------

Cells were harvested and disrupted in a radio-immunoprecipitation assay (RIPA) lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.25% sodium deoxycholate and 1 mM EDTA with protease inhibitor cocktail, 1 mM NaF and 1 mM Na~3~VO~4~). Total protein concentration was measured using a Bradford reagent (Bio-Rad, Hercules, CA) and equal amounts (50 μg) of whole cell lysates were resolved by SDS-PAGE. After electrophoresis, samples were electro-transferred to a nitrocellulose membrane (Bio-Rad), probed with relevant primary antibodies at 4°C overnight, incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA), and detected with an enhanced chemi-luminescence substrate (Amersham, Piscataway, NJ). Antibodies against phospho-c-Met (Y1234/1235), total c-Met, phospho-Akt (S473) and phospho-ERK (T202/Y204) were purchased from Cell Signaling (Danvers, MA), and anti-β-actin (AC-74) antibody was obtained from Sigma (St. Louis, MO).

Recombinant AAV3 vector transduction studies in mouse xenograft models *in vivo* {#S17}
--------------------------------------------------------------------------------

Groups of 6-weeks old NSG mice (Jackson Laboratories, Bar Harbor, ME) were injected subcutaneously with 5×10^6^ Hep293TT or Huh7 cells. Four-week post-injection, indicated numbers of AAV3 vector genomes (vgs) were administered either intratumorally or through tail-vein. Four days post-vector administration, tumors were resected, cross-sectioned and evaluated for EGFP expression using a fluorescent microscope. Sections were also stained with DAPI to visualize the cell nucleus. All animal experiments were conducted in accordance with the University of Florida Institutional Animal Care and Use Committee guidelines.

Statistical analysis {#S18}
--------------------

Results are presented as mean ± standard deviation (SD). Differences between groups were identified using a grouped-unpaired two-tailed distribution of Student's T test. P values \<0.05 were considered statistically significant.
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![Analysis of AAV3-mediated transgene expression in T47D and T47D+hHGFR cells\
**(A)** Equivalent numbers of T47D and T47D+hHGFR cells were infected with various indicated multiplicity-of-infection (MOI) of scAAV3-CBAp-EGFP vectors under identical conditions. Transgene expression was determined by fluorescence microscopy 72 hrs post-infection. **(B)** T47D+hHGFR cells were transduced with 2,000 vgs/cell of scAAV3 vectors in the absence or the presence of 5 μg/ml of hHGF. Transgene expression was determined by fluorescence microscopy 72 hrs post-infection.](nihms-304398-f0001){#F1}

![The effect of BMS-777607 on AAV3-mediated transgene expression\
**(A)** T47D+ hHGFR cells, either mock-treated or treated with various concentration of BMS-777607, were infected with 2,000 vgs/cell of scAAV3-CBAp-EGFP vectors. Transgene expression was determined by fluorescence microscopy 72 hrs post-infection. **(B)** T47D and T47D+hHGFR cells were infected with 10,000 vgs/cell of scAAV3-CBAp-EGFP vectors in the absence or the presence of 1 μM of BMS-777607. **(C)** T47D and T47D+hHGFR cells were mock-treated or pretreated with BMS-777607 for 2 hrs. Whole-cell lysates were prepared and analyzed on Western blots using various indicated primary antibodies. β-actin was used as a loading control.](nihms-304398-f0002){#F2}

![The effect of BMS-777607 on various AAV serotype-mediated transgene expression\
**(A)** T47D+ hHGFR cells, either mock-treated or treated with 1 μM of BMS-777607, were infected with 2,000 vgs/cell of either scAAV2-, scAAV3- or scAAV4-CBAp-EGFP vectors. **(B)** T47D+ hHGFR cells, either mock-treated or treated with 1 μM of BMS-777607, were infected with 2,000 vgs/cell of either scAAV5-, scAAV7-, scAAV8- or scAAV9-CBAp-EGFP vectors. Transgene expression was determined by fluorescence microscopy 72 hrs post-infection.](nihms-304398-f0003){#F3}

![Comparative analyses of AAV3-mediated transduction efficiency in Huh7 and Hep293TT cells with or without treatment with MG132\
**(A)** HeLa cells, either mock-treated or treated with 5 μM of MG132, were infected with scAAV2-CBAp-EGFP vectors. **(B)** Huh7 and Hep293TT cells, either mock-treated or treated with various concentration of MG132, were infected with scAAV3-WT-CBAp-EGFP vectors. **(C)** HeLa cells, either mock-treated or treated with 200 μM of Tyr23, were infected by scAAV2-CBAp-EGFP vectors. **(D)** Hep293TT cells, either mock-treated or treated with Tyr23, were infected by scAAV3-CBAp-EGFP vectors. Transgene expression was determined 72 hrs post-transduction.](nihms-304398-f0004){#F4}

![Site-directed mutational analyses of surface-exposed tyrosine residues on AAV3 capsids\
Huh7 cells were transduced with WT or F501Y scAAV3-CBAp-EGFP vectors under identical conditions, and transgene expression was determined 72 hrs post-transduction **(A)**. Transduction efficiency of WT and various Y-F scAAV3-mediated transgene expression in Huh7 **(B)** and Hep293TT **(C)** cells. Transgene expression was determined 72 hrs post-transduction.](nihms-304398-f0005){#F5}

![Transduction efficiency of WT and single, double, and triple tyrosine-mutant AAV3 vectors\
**(A)** Huh7 cells were transduced with WT or various indicated Y-F mutant scAAV3-CBAp-EGFP vectors under identical conditions. Transgene expression was determined 72 hrs post-transduction. **(B)** Huh7 cells were transduced with 5,000 vgs/cell of WT or Y-F mutant scAAV3 vectors in the absence or the presence of 5 μg/ml of hHGF. Transgene expression was determined by fluorescence microscopy 72 hrs post-infection.](nihms-304398-f0006){#F6}

![Transduction efficiency of AAV3 vectors *in vivo* following direct intra-tumor injections\
Transduction efficiency of WT-AAV3 vectors in **(A)** Huh7- and **(B)** Hep293TT-derived tumors in NSG mice. Transduction efficiency of **(C)** WT- and -- **(D)** Y705+731F-AAV3 vectors in Hep293TT-derived tumors in NSG mice. EGFP fluorescence (green) and DAPI staining (blue) of two representative tumor sections from each set of mice is shown.](nihms-304398-f0007){#F7}

![Transduction efficiency of WT- and Y705+731F-AAV3 vectors in Hep293TT-derived tumors in NSG mice following tail-vein injections\
EGFP fluorescence (green) and DAPI staining (blue) of tumor in three representative tumor sections from each set of mice injected with **(A)** PBS, or **(B)** WT-AAV3, or **(C)** Y705+731F-AAV3 vectors is shown.](nihms-304398-f0008){#F8}

###### 

Surface-exposed tyrosine residues on AAV capsids, and site-directed mutagenesis to phenylalanine residues.

  AAV2   AAV3
  ------ --------
  Y252   Y252→F
  Y272   Y272→F
  Y444   Y444→F
  Y500   F501
  Y700   Y701→F
  Y704   Y705→F
  Y730   Y731→F

The surface-exposed tyrosine (Y) residues on AAV2 and AAV3 capsids are shown; red arrows denote the site-directed mutations from Y to phenylalanine (F) residues on AAV3 capsids.

###### 

Nucleotide sequences of primers used for site-directed mutagenesis.

  --------------------------------------------------------------------
  Mutants   Primer sequences (5′-3′)
  --------- ----------------------------------------------------------
  Y252F     ACCAGAACCT[GGGCTC]{.ul}TGCCCACTTTCAACAACCATCTCTACAAG\
                -ApaI  Tyr→Phe

  Y272F     CAATCAGGAGC[TTCGAA]{.ul}CGACAACCACTTCTTTGGCTACAGCACC\
                +BstBI  Tyr→Phe

  Y444F     CTT[ATCGAT]{.ul}CAGTATCTGTACTTCCTGAACAGAACGCAAGGAACA\
             +ClaI    Tyr→Phe

  F501Y     GCTAACGACAACAACAACAGTAACTAT[CCATGG]{.ul}ACAGCGGCCAGCAAA\
                Phe→Tyr +NcoI

  Y701F     TGGAATCCAGAGATTCAGTT[CACGTC]{.ul}CAACTACAACAAGTCTGTT\
               Tyr→Phe +BmgBI

  Y705F     GAGATTCAGT[ACACGT]{.ul}CCAACTTCAACAAGTCTGTTAATGTGGAC\
              +AflIII  Tyr→Phe

  Y731F     GTGAACCTCGCCCTATTGGAACCCGGTTTCTCACACGAAACTTG\
                 Tyr→Phe
  --------------------------------------------------------------------

The codon triplets are shown in bold; red fonts denote the mutations from tyrosine to phenylalanine residues, and green fonts indicate the silent mutations to eliminate/create the restriction enzyme sites (underlined), which were used to identify the desired clones.

[^1]: Binbin Cheng and Chen Ling contributed equally to this work
